264 related articles for article (PubMed ID: 9396784)
1. Constitutive activity of a chimeric D2/D1 dopamine receptor.
Kozell LB; Neve KA
Mol Pharmacol; 1997 Dec; 52(6):1137-49. PubMed ID: 9396784
[TBL] [Abstract][Full Text] [Related]
2. Chimeric D1/D2 dopamine receptors. Distinct determinants of selective efficacy, potency, and signal transduction.
Kozell LB; Machida CA; Neve RL; Neve KA
J Biol Chem; 1994 Dec; 269(48):30299-306. PubMed ID: 7982941
[TBL] [Abstract][Full Text] [Related]
3. Dopamine D5 receptor agonist high affinity and constitutive activity profile conferred by carboxyl-terminal tail sequence.
Demchyshyn LL; McConkey F; Niznik HB
J Biol Chem; 2000 Aug; 275(31):23446-55. PubMed ID: 10807903
[TBL] [Abstract][Full Text] [Related]
4. Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors.
Perachon S; Schwartz JC; Sokoloff P
Eur J Pharmacol; 1999 Feb; 366(2-3):293-300. PubMed ID: 10082211
[TBL] [Abstract][Full Text] [Related]
5. Reconstitution of functional dopamine D(2s) receptor by co-expression of amino- and carboxyl-terminal receptor fragments.
Scarselli M; Armogida M; Chiacchio S; DeMontis MG; Colzi A; Corsini GU; Maggio R
Eur J Pharmacol; 2000 Jun; 397(2-3):291-6. PubMed ID: 10844126
[TBL] [Abstract][Full Text] [Related]
6. Sensitization of endogenous and recombinant adenylate cyclase by activation of D2 dopamine receptors.
Watts VJ; Neve KA
Mol Pharmacol; 1996 Oct; 50(4):966-76. PubMed ID: 8863843
[TBL] [Abstract][Full Text] [Related]
7. Dopamine receptor activation in bovine pinealocyte via a cAMP-dependent transcription pathway.
Santanavanich C; Ebadi M; Govitrapong P
J Pineal Res; 2005 Apr; 38(3):170-5. PubMed ID: 15725338
[TBL] [Abstract][Full Text] [Related]
8. Dopamine D1B receptor chimeras reveal modulation of partial agonist activity by carboxyl-terminal tail sequences.
Sugamori KS; Scheideler MA; Vernier P; Niznik HB
J Neurochem; 1998 Dec; 71(6):2593-9. PubMed ID: 9832160
[TBL] [Abstract][Full Text] [Related]
9. Biochemical identification of the dopamine D2 receptor domains interacting with the adenosine A2A receptor.
Torvinen M; Kozell LB; Neve KA; Agnati LF; Fuxe K
J Mol Neurosci; 2004; 24(2):173-80. PubMed ID: 15456930
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological characterization of mammalian D1 and D2 dopamine receptors expressed in Drosophila Schneider-2 cells.
Schetz JA; Kim OJ; Sibley DR
J Recept Signal Transduct Res; 2003 Feb; 23(1):99-109. PubMed ID: 12680592
[TBL] [Abstract][Full Text] [Related]
11. Patterns of cyclic AMP formation by coexpressed D1 and D2L dopamine receptors in HEK 293 cells.
Sakolsky DJ; Ashby B
Recept Channels; 2001; 7(6):479-89. PubMed ID: 11918350
[TBL] [Abstract][Full Text] [Related]
12. Constitutive coupling of a chimeric dopamine D2/alpha 1B receptor to the phospholipase C pathway: inverse agonism to silent antagonism by neuroleptic drugs.
Wurch T; Boutet-Robinet EA; Palmier C; Colpaert FC; Pauwels PJ
J Pharmacol Exp Ther; 2003 Jan; 304(1):380-90. PubMed ID: 12490615
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological characterization of dopamine receptors in the corpus allatum of Manduca sexta larvae.
Granger NA; Ebersohl R; Sparks TC
Insect Biochem Mol Biol; 2000; 30(8-9):755-66. PubMed ID: 10876119
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional activation of phosphodiesterase 7B1 by dopamine D1 receptor stimulation through the cyclic AMP/cyclic AMP-dependent protein kinase/cyclic AMP-response element binding protein pathway in primary striatal neurons.
Sasaki T; Kotera J; Omori K
J Neurochem; 2004 Apr; 89(2):474-83. PubMed ID: 15056290
[TBL] [Abstract][Full Text] [Related]
15. The agonist activities of the putative antipsychotic agents, L-745,870 and U-101958 in HEK293 cells expressing the human dopamine D4.4 receptor.
Gazi L; Bobirnac I; Danzeisen M; Schüpbach E; Bruinvels AT; Geisse S; Sommer B; Hoyer D; Tricklebank M; Schoeffter P
Br J Pharmacol; 1998 Jul; 124(5):889-96. PubMed ID: 9692773
[TBL] [Abstract][Full Text] [Related]
16. Dopamine D2L receptors stimulate Na+/K(+)-ATPase activity in murine LTK- cells.
Yamaguchi I; Walk SF; Jose PA; Felder RA
Mol Pharmacol; 1996 Feb; 49(2):373-8. PubMed ID: 8632772
[TBL] [Abstract][Full Text] [Related]
17. Identification of transmembrane regions critical for ligand binding to the human D3 dopamine receptor using various D3/D1 transmembrane chimeras.
Alberts GL; Pregenzer JF; Im WB
Mol Pharmacol; 1998 Aug; 54(2):379-88. PubMed ID: 9687580
[TBL] [Abstract][Full Text] [Related]
18. Effects of dopamine D1 ligands on eye blinking in monkeys: efficacy, antagonism, and D1/D2 interactions.
Jutkiewicz EM; Bergman J
J Pharmacol Exp Ther; 2004 Dec; 311(3):1008-15. PubMed ID: 15292458
[TBL] [Abstract][Full Text] [Related]
19. Determination of D1 and D2 dopamine receptor expression by Ntera-2 cells.
Sakolsky DJ; Ashby B
Brain Res Mol Brain Res; 2000 Dec; 84(1-2):158-61. PubMed ID: 11113544
[TBL] [Abstract][Full Text] [Related]
20. Dopamine D1- and D2-like receptor mechanisms in relapse to cocaine-seeking behavior: effects of selective antagonists and agonists.
Khroyan TV; Barrett-Larimore RL; Rowlett JK; Spealman RD
J Pharmacol Exp Ther; 2000 Aug; 294(2):680-7. PubMed ID: 10900248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
